Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @SilenceTheraPlc
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @SilenceTheraPlc
-
Silence Therapeutics proslijedio/la je Tweet
$SLN Silence Therapeutics CEO talks recent RNAi deals and updates on critical SLN124 trial http://tinyurl.com/rld23kx via@proactive_UK@SilenceTheraPlc#SLN#brighterir#AndrewScottTVHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Silence Therapeutics proslijedio/la je Tweet
$SLN@SilenceTheraPlc Chief executive, David Solomon, updates on#developments across three key#programmes - SLN 500, 124 and 360. Discussing the firm's current valuation, Solomon says ''there's a lot more steam in the engine''#SLN Full interview here - https://bddy.me/2JsAj8S pic.twitter.com/r38tpAcerFHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Silence Therapeutics, a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, today announces its unaudited interim results for the half year to 30 June 2019. https://www.silence-therapeutics.com/media/1964/sln-half-year-2019-results-announcement.pdf …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Silence Therapeutics proslijedio/la je Tweet
Mallinckrodt, Silence Therapeutics partner to develop RNAi therapies for complement-mediated diseases https://www.firstwordpharma.com/node/1653697
$MNK$SLNHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Silence Therapeutics proslijedio/la je Tweet
Interview: Mallinckrodt Deal Golden For Silence Therapeutics http://bit.ly/2SrP9Qd
#PharmaScripHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
David Solomon, CEO of Silence Therapeutics, discussing the transformational deal with Mallinckrodt at Proactive Investors. Watch the full video herehttps://www.youtube.com/watch?v=hXju3ivYlpM …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
David Solomon commenting of the collaboration with
@MNKpic.twitter.com/EY9L4hPvEa
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Very pleased to announce the collaboration between Silence Therapeutics and
@MNK to fight the unmet needs of rare diseases as well as conditions of immune dysregulations. Watch our CEO, David Solomon speak about this collaboration herehttps://youtu.be/ID8FQDj5iOoHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
We are delighted to announce that Silence Therapeutics is collaborating with
@MNK to allow the companies to develop and commercialize RNAi drug targets designed to inhibit the complement cascade. Read more about the collaboration in our press release https://www.silence-therapeutics.com/media/1953/silence-therapeutics-and-mallinckrodt-announce-collaboration.pdf …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Silence Therapeutics is pleased to announce the appointment of Giles Campion, MD as Head of R&D and Chief Medical Officer, effective 1 June 2019. https://www.silence-therapeutics.com/media/1906/160419-head-rd-rns.pdf …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Silence Therapeutics, PLC announces that a CTA for the Company’s lead candidate SLN124 has been submitted to the UK MHRA. https://www.silence-therapeutics.com/media/1900/sln124-cta-announcement.pdf …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Silence Therapeutics, PLC announces its unaudited preliminary results for the year ended 31 December 2018. https://www.silence-therapeutics.com/media/1895/sln-2018-preliminary-results-announcement.pdf …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Silence Therapeutics announces that its lead medicine candidate SLN124 has been granted Orphan Drug Designation by the EMA for the treatment of β-Thalassemia. https://www.silence-therapeutics.com/media/1874/190115-silence-sln124-orphan-drug-status-rns.pdf …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Silence Therapeutics announces the addition of a new siRNA (short interfering RNA) asset to its pre-clinical pipeline for the potential treatment of cardiovascular disease. https://www.silence-therapeutics.com/media/1863/lp-a-rns.pdf …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Silence Therapeutics to attend Haemochromatosis UK reception at The House of Commons, Westminster on Wednesday, October 31, 2018 at 4pm. https://www.silence-therapeutics.com/media/1845/silence-therapeutics-to-participate-in-haemochromatosis-uk-reception.pdf …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Silence Therapeutics plc today reports on the favourable outcome of a decision by the US PTAB against Alnylam. https://www.silence-therapeutics.com/media/1843/11th-october-rns-us-pgr-success.pdf …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Silence Therapeutics Announces Receipt of a New European Notice of Intention to Grant a Patent and the Launch of an Interim European Injunction Application against Onpattro™ https://www.silence-therapeutics.com/media/1842/10-october-silence-rns-injunction-application.pdf …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Silence Therapeutics plc announces that David Horn Solomon, Chief Executive Officer, will present at the Cantor Fitzgerald 2018 Global Healthcare Conference on Wednesday, October 3, 2018 at 12:15pm EDT in New York, NY. https://www.silence-therapeutics.com/media/1839/silence-therapeutics-cantor-conf-announcement.pdf …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Silence Therapeutics proslijedio/la je Tweet
$SLN Silence Therapeutics to kick off first in-human clinical trial next year http://tinyurl.com/y8uba8rd via@proactive_UK@SilenceTheraPlc#SLN#brighterir#AndrewScottTV#CapitalNetwork1Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Silence Therapeutics plc, AIM:SLN a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases, announces its unaudited interim results for the half year to 30 June 2018. https://www.silence-therapeutics.com/media/1831/sln-half-year-2018-press-release.pdf …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.